Advertisement
Australia markets closed
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • AUD/USD

    0.6514
    +0.0014 (+0.22%)
     
  • OIL

    82.94
    +0.13 (+0.16%)
     
  • GOLD

    2,330.50
    -7.90 (-0.34%)
     
  • Bitcoin AUD

    98,701.64
    -3,555.25 (-3.48%)
     
  • CMC Crypto 200

    1,389.62
    +7.04 (+0.51%)
     
  • AUD/EUR

    0.6076
    +0.0006 (+0.10%)
     
  • AUD/NZD

    1.0954
    +0.0012 (+0.11%)
     
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,212.00
    +10.73 (+0.06%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Maravai LifeSciences Announces March 2021 Investor Conference Schedule

SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in two upcoming virtual investor conferences.

On March 3, 2021, Carl Hull, Chief Executive Officer, is scheduled to present at the Cowen Health Care Conference at 10:20 a.m. PT.

On March 23, 2021, Hull will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum at 8:30 a.m. PT.

A live webcast of the presentations will be available to all interested parties on the Maravai Lifesciences investor relations website at http://investors.maravai.com. An archived version of the webcast will be available a few hours following the completion of each event on the Maravai investor relations website.

ADVERTISEMENT

About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit www.maravai.com.

CONTACT: Contact Information: Media Contact: Sara Michelmore MacDougall +1 781-235-3060 maravai@macbiocom.com Investor Contact: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@maravai.com